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Abstract
Viral reactivation is one of the most serious complications for immunocompromised
patients.  Under  immunosuppressive  conditions,  some  viruses  can  be  reactivated
solely or simultaneously and may thus cause life-threatening infection. Therefore, the
prompt and proper diagnosis of viral reactivation is important for the initiation of
preemptive  therapy.  For  this  purpose,  we  recently  developed  a  multiplex-virus
polymerase  chain  reaction  (PCR)  assay.  The  multiplex  PCR  assay  is  designed  to
qualitatively  measure  the  genomic  DNA  of  12  viruses  at  once:  cytomegalovirus
(CMV), human herpesvirus type 6 (HHV-6), HHV-7, HHV-8, Epstein-Barr virus (EBV),
varicella-zoster  virus  (VZV),  BK  virus  (BKV),  JC  virus  (JCV),  parvovirus  B19
(ParvoB19), herpes simplex virus type 1 (HSV-1), HSV-2, and hepatitis B virus (HBV).
When a specific PCR signal is obtained, the viral load is determined by a quantitative
real-time PCR. The qualitative multiplex and quantitative real-time PCR procedures
take only 3 hours to complete. With this assay system, we can identify viremia at the
early stage and thereby prevent it from progressing to overt and symptomatic viral
infection  in  immunocompromised  patients,  such  as  those  receiving  hematopoietic
stem cell transplantation.
Keywords: multiplex PCR, viral infection, viral reactivation, immunocompromised
host, hematopoietic stem cell transplantation, immunosuppressive therapy
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1. Introduction
Viral reactivation is a major cause of morbidity and mortality in patients receiving chemo-
therapy, immunosuppressive therapy, and hematopoietic stem cell transplantation (HSCT).
This occurs in a host via an internal or an external trigger, such as immunosuppression, to
activate from the latent state of viral infection, which lasts for a long time following primary
infection. In immunocompromised hosts, some viruses can be reactivated solely or simulta-
neously and may cause life-threatening infection, such as pneumonia, meningitis, encephalitis,
and lymphoproliferative disorders [1, 2]. Therefore, the prompt and appropriate detection of
viral reactivation is important for the initiation of preemptive therapy. Among viruses that
cause these infections, human herpes and polyoma family viruses are important in patients in
an immunocompromised state.
Polymerase chain reaction (PCR) is a useful tool for detecting or monitoring viral genomes.
However, a conventional viral PCR assay detects only a single virus. Therefore, we recently
developed a qualitative multiplex PCR assay to quickly and simultaneously detect 12 kinds of
viral DNA genomes, including eight herpes family viruses, from various samples such as
blood [3–5], cerebrospinal fluid (CSF), ocular fluid [6, 7], bronchoalveolar lavage fluid [8],
urine, and gastrointestinal mucosa. This qualitative multiplex PCR assay can be combined with
quantitative real-time PCR to determine the viral load when a specific PCR signal is detected
by the multiplex PCR.
In this chapter, we describe the frequency of viral reactivation and its clinical significance in
immunocompromised patients, such as those with hematologic malignancies, inflammatory
bowel diseases, and collagen diseases, with special relevance in patients receiving allogeneic
hematopoietic stem cell transplantation (HSCT).
2. Materials and methods
2.1. Samples
From April 2011 to May 2016, specimens were obtained for monitoring viral infections from
blood, urine, cerebrospinal fluid, and intestinal mucosa from patients in Shinko Hospital
and the Pediatric Department of Kyoto University Hospital, when patients developed symp-
toms such as fever, cough, headache, consciousness disorder, liver dysfunction, nausea, ab-
dominal pain, and diarrhea. Blood samples were obtained as negative controls from 12
healthy volunteers with informed consent. The present study was a single institutional clini-
cal study designated “Multiple Virus-Analytic Study by Multiplex PCR” and was approved
by the review board of Shinko Hospital. Individual patients provided their written in-
formed consent.
The plasma was separated from ethylenediaminetetraacetic acid (EDTA)-2Na-chelated whole
blood, and the supernatants were obtained from the urine and cerebrospinal fluid (CSF). DNA
was extracted from 400 μl of these samples using a QIAamp MinElute Virus Spin Kit (Qiagen,
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Valencia, CA, USA). DNA was extracted from gastrointestinal mucosa using a QIAamp DNA
mini kit (Qiagen) and eluted with 100-μl elution buffer.
2.2. Multiplex-virus PCR assay
The multiplex-virus PCR was designed to identify the following 12 species of virus at once:
cytomegalovirus (CMV), human herpesvirus type 6 (HHV-6), HHV-7, HHV-8, Epstein-Barr
virus (EBV), varicella-zoster virus (VZV), BK virus (BKV), JC virus (JCV), parvovirus B19
(ParvoB19), herpes simplex virus type 1 (HSV-1), HSV-2, and hepatitis B virus (HBV). The
sequences of the primers and probes for these 12 viruses have been described [3]. Multiplex
PCR amplifications were set up in two capillaries: capillary A was for HSV-1, HSV-2, VZV,
HHV-6, CMV, Parvo B19, BKV, and JCV, and capillary B was for EBV, HHV-7, and HHV-8. Each
capillary contained 5-μl DNA extract, specific primers, and AccuprimeTaq (Invitrogen,
Carlsbad, CA, USA). The PCRs were performed using a LightCycler (Roche, Basel, Switzer-
land) with the following protocol: an initial denaturation step for 2 min at 95 °C, followed by
40 PCR cycles at 95 °C, then 2 s at 58 °C, and then 15 s at 72 °C. Hybridization probes were
then mixed with the PCR products by 3000-rpm centrifugation for 3 s, and the melting curves
were analyzed using a LightCycler (Roche) with the following protocol: an initial denaturation
step for two cycles of 0 s at 40 °C, then 10 s at 95 °C, followed by hybridization at 40 °C for 20
s and melting at 40–80 °C (ramp rate, 0.2 °C/s). Specific hybridization with probes and
individual PCR products were dissociated at the specific temperature for each virus and, as a
result, the fluorescence signal disappeared (Figure 1).
Figure 1. The melting curve analysis of multiplex-virus PCR.
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Virus Primer sequence Probe sequence
HSV1/
HSV2 
F: CGCATCAAGACCACCTCCTC  P: Cy5-TGGCAACGCGGCCCAAC-iowaBK 
  R: GTCAG CTCGTG RTTCTG  P: 3FAM-CGGCGAIGCGCCCAG-iowaBK 
VZV  F: TCACTACCAQTCATTTCTATCCATCTG  P: HEX-TGTCTTTCACGGAGGCAAACACGT-
iowaBK 
  R: GAAAACCCAAACCGTTCTCGAG   
EBV  F: CTGGGCAAG G AG CTGTTG  P: 6FAM-CTCGGCTGTGGAGCAGGCTT-iowaBK 
  R: GGrCGrTTGTAAAATTGCA   
CMV  F: TCG CGCCCGAAGAGG  P: Cy5-CACCGACGAGGATTCCGACAACG-iowaBK 
  R: CGGCCGGATTGTGGATT  P: Cy5-CACCGACGGATTCCGACAACG-iowaBK 
HHV6  F: GAAGCAGCAATCGCAACACA  P: Cy5-AACCCGTGCGCCGCTCCC-iowaBK 
  R: ACAACATGTAACTCGGTGTACGGT  P: Cy5-AACCCGTGCGCCGCTCCC-iowaBK 
HHV7  F: CGGAAGTCACTGGAGTAATGACAA  P: HEX-CTCGCAGATTGCTTGCTTGCTTGGCCATG-
iowaBK 
  R: ATCGTTGCCTATTTCTTTTTGCC   
BKV/JCV  F: GGAAAGTCTTTAGGGTCTTCTACCTTT  P: 6FAM-ATCACTGGCAAACAT-MGB 
  R: GATGAAGATTTATTYTGCCATGARG   
Parvo B19  F: GGGTTTCAAGCACAAGYAGTAAAAGA P: 6FAM-CAGCTGCCCCTGTGG-MGB 
  R: CGGYAAACTTCCTTG AAAATG   
ADV  F: GACATGACTTTTGAGGTGGA  P: 6FAM-CCCATGGAYGAGCCCACCCT-BHQ 
  R: TCGATGACGCCGCGGTG   
HBV  F: GTGGTGGACTTCTCTCAATTFTCTAG  P: 6FAM-TGTCTGCGGCGTTTT-MGB 
  R: GGACAMACGGGCAACATACTT  P: 6FAM-TGTCTGCGGCGTTTT-MGB 
Table 1. The sequences of primers and probes used for the multiplex PCR assay.
More recently, a more convenient multiplex-virus PCR method adding adenovirus (ADV)
detection was developed using a solid-phase plate. The primers and probes are fixed in
advance as a solid phase on seven-well plates (Nihon Techno Service, Ibaraki, Japan), as
follows: well A is for TBP and GADPH; well B for HSV-1 and HBV; well C for BKV and HHV-7;
well D for EBV and VZV; well E for HHV-6, HSV-2, and HHV-8; well F for ADV and JCV; and
well G for CMV and ParvoB19. The probes in the corresponding wells were labeled with four
kinds of fluorochromes: 6FAMTM, HEXTM, Cy5TM, and ROXTM. The sequences of primers and
probes employed in this assay system are listed in Table 1. The reaction mixture at a final
volume of 20 μl consisted of 2-μl DNA extract (100–300 ng/well), 10-μl buffer, 0.2-μl Taq
enzyme (Nihon Techno Service, Ibaraki, Japan), and 7.8 μl dH2O. The reaction mixture was
placed in each well described above, dissolving the solid-phase primers and probes, to create
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the final reaction solution. The wells were then capped and centrifuged for 3000 rpm for 3 s.
Amplification and real-time fluorescence detection were performed with a model 7500 Real-
Time PCR System (Applied Biosystems, CA, USA) with the following protocol: an initial
denaturation step for 10 s at 95 °C, followed by 45 PCR cycles at 95 °C for 5 s and 60 °C for 30
s. Of note, a plate already fixed with a Taq enzyme in the solid phase in addition to the advanced
fixation of primers and probes will be available in the near future from Shimadzu Corporation
(Kyoto, Japan).
A sensitivity test for multiplex PCR was performed using known plasmid DNA representatives
for the 12 individual DNA viruses. The plasmid DNAs were synthesized by Nihon Techno
Service Company (Ibaraki, Japan). We confirmed that a minimum of 50 copies of each virus
(5 × 103 copies/ml) could be detected by both the capillary and solid-phase plate systems with
the plasmid DNAs at various dilutions [3, 5].
As described previously, when a specific PCR signal was obtained with the multiplex-virus
PCR, the sample was subjected to subsequent quantitative real-time PCR assay to measure the
viral load [3].
2.3. Statistical analysis
The cutoff value from the receiver operator characteristic (ROC) curves was evaluated for the
sensitivity and specificity. A statistical analysis was performed using the EZR software
program (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a
modified version of the R software package that contains a graphical user interface and is
designed for statistical functions that are frequently used in biostatistics (The R Foundation
for Statistical Computing, Vienna, Austria) [9].
3. Results and discussion
We analyzed 2450 blood, 173 CSF, 129 intestinal mucosa, 483 urine samples, 18 ocular fluids,
and 123 bronchoalveolar lavage fluids from 858 patients between February 2011 and May 2016
(Table 2). The patients included 117 who underwent allogeneic HSCT; 741 treated with
chemotherapy or immunosuppressive therapy for hematologic malignancies, autoimmune
diseases, and inflammatory bowel diseases, and a small number of immunocompetent hosts.
The HSCT patients included 30 adults and 87 children.
3.1. Detection of viral DNAs in plasma samples
3.1.1. Viremia in immunocompromised patients
Multiplex PCR detected HSV-1 in 21 (0.9%), VZV in 24 (1.0%), EBV in 224 (9.1%), CMV in
430 (17.6%), HHV-7 in 11 (0.4%), HHV-6 in 209 (8.5%), Parvo B19 in 9 (0.4%), BKV in 163
(6.6%), JCV in 13 (0.5%), and HBV in 16 (0.7%) samples of 2450 blood samples from all
patients (Table 2). Neither HSV-2 nor HHV-8 was detected in any of the samples. None of
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the 12 DNA viruses were detected in any of the 12 healthy volunteers. The frequency of viral
detection in patients who received allogeneic HSCT was higher than in patients treated with
chemotherapy or immunosuppressive therapy. The most frequently detected virus in
allogeneic HSCT patients was CMV (48.7%; 52/117), followed by HHV-6 (41.9%; 49/117), and
EBV (29.9%; 35/117). Multiple detection of ≧2 viruses was observed in 8.1% patients (198/2450
samples), and coinfection with 4 kinds of viruses was observed in 3 cases. The most frequent
coinfection in all samples was a combination of CMV and EBV (1.9%; 47/2450), followed by
CMV and HHV-6 (1.3%; 33/2450). Coinfection of CMV and HHV-6 was observed more
frequently in allogeneic HSCT patients (11.1%; 13/117) than in the other patients (0.4%; 3/741).
Virus Plasma Plasma(allo-
HSCT)
CSF Urine Ocular fluid BALF
Sample
number
Positive
(%)
Sample
number
Positive
(%)
Sample
number
Positive
(%)
Sample
number
Positive
(%)
Sample
number
Positive
(%)
Sample
number
Positive
(%)
HSV-1 21/2450 0.9 15/1395 0.9 6/173 34.7 0 0 1/18 5.6 1/123 0.8
HSV-2 0 0 0 0 4/173 23.1 0 0 0 0 0 0
VZV 24/2450 1 13/1395 0.9 6/173 3.5 0 0 2/18 11.1 1/123 0.8
CMV 430/2450 17.7 284/1395 20.4 1/173 0.6 14/380 3.7 3/18 16.7 13/123 10.6
HHV-6 209/2450 8.5 164/1395 11.8 8/173 4.6 7/380 1.8 1/18 5.6 3/123 2.4
HHV-7 11/2450 0.4 4/1395 0.3 0 0 0 0 0 0 7/123 5.7
HHV-8 0 0 0 0 0 0 0 0 0 0 0 0
EBV 224/2450 9.1 116/1395 8.3 2/173 1.2 4/380 1.1 2/18 11.1 39/123 31.7
BKV 163/2450 6.6 119/1395 8.5 3/173 1.7 194/380 51.1 0 0 1/123 0.8
JCV 13/2450 0.5 2/1395 0.1 2/173 1.2 54/380 14.2 0 0 0 0
HBV 16/2450 0.7 6/1395 0.4 1/173 0.6 0 0 0 0 0 0
ParvoB12  9/2450 0.4 0 0 1/173 0.6 0 0 0 0 0 0
ADV N.D. 0 N.D. – N.D. – 65/350 18.6 N.D. – N.D. –
allo-HSCT; allogenic hematopoietic stem cell transplantation, BALF;bronchoalveolar fluid, N.D.; not determined.
Table 2. Absolute numbers and percentages of PCR-positive specimens separated by material.
3.1.2. Multiplex-virus PCR and CMV antigenemia assay
The correlation of the results by multiplex-virus PCR and those by CMV antigenemia assay
(LSI Medience Corp., Tokyo, Japan), which has been widely used to monitor CMV reactivation,
was examined using 144 plasma samples. In Japan, preemptive therapy is usually conducted
when the antigenemia test gives three positive cells/two slides, as a criterion for preventing
CMV disease. In our study, the virus multiplex PCR negativity corresponded to a median 0
positive cells/2 slides (range: 0–19) by the CMV antigenemia method, and the PCR positivity
corresponded to a median 5 positive cells/2 slides (range: 0–419, P < 0.001). The median CMV
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DNA copy number determined by quantitative real-time PCR was 280 copies/ml (0–11,000)
and 13,000 copies/ml (70–500,000) in negative and positive samples by multiplex PCR,
respectively (P < 0.0001). An ROC curve analysis showed that a CMV viral load of 2400 copies/
ml in the plasma corresponded to 3 positive cells/2 slides by CMV antigenemia (sensitivity:
88.9%, specificity: 80.2%) and that a CMV viral load of 120 copies/ml in plasma was the
threshold value of positivity by multiplex PCR (sensitivity: 95.6%, specificity: 81.2%). These
results indicated that multiplex-virus PCR was able to detect the level of the CMV viral load
to determine whether or not antiviral therapy should be started, and quantitative PCR was
indispensable for determining the need for preemptive therapy.
3.1.3. Viremia in allogeneic HSCT patients
Using this multiplex PCR assay, Inazawa et al. prospectively examined 105 patients who
underwent allogeneic HSCT once a week for viral reactivation, from pretransplantation to 42-
day posttransplantation. The detection of viremia peaked at 21 days posttransplantation, and
the most frequently detected virus was HHV-6 (60.0%), followed by EBV (10.5%), CMV (10.5%),
and HHV-7 (8.6%). Cord blood transplantation, steroid treatment, and anti-thymoglobulin use
were significant risk factors for viral reactivation after allogeneic HSCT [5].
3.1.4. Viremia in patients with liver dysfunction
Using a multiplex-virus PCR assay and subsequent quantitative real-time PCR, Ito et al.
examined 37 patients with unexplained liver dysfunction not due to HBV or hepatitis C virus
(HCV) infection for 12 species of DNA viruses and 6 RNA hepatitis virus (hepatitis A virus,
HCV, hepatitis D virus, hepatitis E virus, hepatitis G virus, and transfusion-transmitted virus;
TTV). The patients included 19 with hematologic disease and 18 with immunocompetence or
other diseases. The detected viruses were TTV (38% of patients), HHV-6 (35%), EBV (14%),
CMV (8%), hepatitis G virus (3%), and HHV-7 (3%). The relationship between liver dysfunction
and HHV-6, EBV, and CMV infections was confirmed based on the time course of liver
dysfunction and the detection of these viruses [3].
3.1.4.1. Case presentation 1: early diagnosis of visceral disseminated VZV infection by multiplex-
virus PCR
A 48-year-old female underwent unrelated allogeneic HSCT for acute myeloid leukemia and
received immunosuppressive therapy with tacrolimus. Four months after the transplantation,
she developed severe abdominal pain. Computed tomography and upper gastrointestinal
endoscopy were unremarkable; however, VZV-DNA was detected in the plasma by multiplex-
virus PCR as a screening test, and a high copy number of VZV (65,000 copies/ml) was confirmed
by the quantitative PCR. A diagnosis of visceral-disseminated VZV infection was made. Three
days after starting intravenous acyclovir, she developed vesicular eruptions and hypoesthesia
on the right leg. A high level of VZV (14,000 copies/ml) was also detected in the cerebrospinal
fluid (CSF), indicating she also had meningitis/myelitis. Her symptoms were improved, and
VZV-DNA became undetectable in both plasma and CSF after the dosage of acyclovir was
increased. Visceral-disseminated VZV infection is a life-threatening disease associated with a
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high mortality rate in patients following up HSCT and organ transplantation [10, 11]. Screening
by multiplex-virus PCR was very useful in terms of the early diagnosis of VZV disease and
consequent treatment.
3.1.4.2. Case presentation 2: the role of multiplex-virus PCR in intestinal complications after
allogeneic HSCT
A 58-year-old female underwent allogeneic HSCT for high-risk myelodysplastic syndrome.
She developed abdominal pain and severe diarrhea 1 month after the transplantation.
Colonofiberscopy showed diffuse mucosal erosion and edema. The multiplex-virus PCR did
not detect any virus DNA in the blood or intestinal mucosa. The histopathological diagnosis
was intestinal graft-versus-host disease (GVHD). Parenteral methylprednisolone was started
in addition to tacrolimus, but her symptoms were not improved. CMV was detected in the
plasma 2 weeks after the initiation of methylprednisolone, and the virus copy number was 180
copies/ml. Another colonofiberscopy revealed exacerbation of mucosal erosion and edema,
and CMV became detectable in both the intestinal mucosa and plasma by multiplex-virus PCR.
At this time, the CMV copy number in the intestinal mucosa and plasma were 33,000 and 47,000
copies/ml, respectively. Treatment with ganciclovir was started. On an immunohistochemical
examination, CMV-infected cells were observed in the intestinal mucosa in addition to GVHD
histologic features. Her abdominal symptoms lasted for 3 months but were gradually im-
proved by treatment of both GVHD and CMV infection. In this patient, intestinal GVHD was
complicated by CMV colitis, and it was difficult to distinguish the CMV colitis from intestinal
GVHD by endoscopy because a histopathological examination takes some time. In this setting,
the multiplex-virus PCR examination was useful because the PCR assay enabled us to perform
early intervention for CMV infection and prevent exacerbation of the viral disease.
3.2. Virus detection in CSF samples from patients with central nervous system (CNS)
symptoms
A total of 173 CSF samples were obtained from 142 patients with central nervous system (CNS)
symptoms, such as a fever with headache and consciousness disturbance. The most frequently
detected viruses by the multiplex-virus PCR were HHV-6 (N = 9; 5.2%), followed by HSV-1(N
= 6; 3.5%), VZV (N = 6; 3.5%), HSV-2 (N = 4; 2.3%), BKV (N = 3; 1.7%), EBV (N = 2; 1.2%), JCV
(N = 2; 1.2%), CMV (N = 1; 0.6%), ParvoB12 (N = 1; 0.6%), and HBV (N = 1; 0.6%) (Table 2).
HHV-6 was detected in the CSF in 17.1% of patients who underwent allogeneic HSCT, a
significantly higher prevalence than that in the remaining patients (1.4%) who received
chemotherapy and immunosuppressive therapy. In one patient who received allogeneic HSCT,
HSV-1 and BKV were simultaneously detected when the patient was complicated by con-
sciousness disturbance. HHV-7 and HHV-8 were not detected in all patients. The median
HHV-6 copy numbers in the CSF and plasma samples at the same time were 3800 (range: 290–
110,000) and 1250 (range: 10–1900) copies/ml, respectively, indicating a higher HHV-6 load in
the CSF than in the blood.
HHV-6 encephalitis after allogeneic HSCT is a serious and potentially fatal complication. The
reported incidence of this encephalitis after allogeneic HSCT varies from 0 to 21.4%, and it
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typically occurs around 2–6 weeks after transplantation [12, 13]. The incidence of HHV-6
detection in CSF in our institution tended to be higher than that reported in previous studies,
possibly due to frequent monitoring of HHV-6 in the plasma and CSF during longer follow-
up after transplantation. A recent prospective study reported that a high-plasma HHV-6 load
is associated with an increased risk of developing HHV-6 encephalitis [14]. In particular, a
plasma HHV-6 load exceeding 10,000 copies/ml significantly increases the risk of HHV-6
encephalitis following allogeneic HSCT [14]. In comparison with previous reports, our patients
had relatively low copy numbers of HHV-6 in both the plasma and CSF. Although the reason
for this difference in results is unclear, it may be due to different quantitative PCR methodol-
ogies or differences in the sampling time.
Human herpesviruses other than HHV-6 (HSV, VZV, HHV-7, CMV, and EBV) and two human
polyomaviruses (BKV and JCV) also cause serious meningitis or encephalitis [15, 16]. These
viruses are latent in many sites, including the CNS and hematopoietic cells after primary
infection during childhood or adulthood [15, 17–20]. Encephalitis caused by reactivation of
these viruses can develop even in healthy individuals, as well as in immunocompromised
hosts. However, immunocompromised hosts are at a higher risk of severe disease and
mortality [21], and even in those that survive, a majority are left with serious neurologic
impairments, such as memory disturbance and seizure [22]. Therefore, the early diagnosis by
multiplex-virus PCR and preemptive therapy is of great importance, although the standardi-
zation of the PCR method is needed.
3.2.1. Case presentation 3: convulsion attack during the treatment with foscavir after allogeneic HSCT
A 25-year-old man underwent allogeneic HSCT for acute lymphoblastic leukemia, and mon-
itoring for viral reactivation was performed weekly using multiplex-virus PCR. Four weeks
after transplantation, HHV-6 was detected in the plasma at a viral load of 120,000 copies/ml.
The HHV-6 viral load was decreased to 1200 copies/ml 1 week after the initiation of foscavir
therapy, but the patient developed convulsions with consciousness disturbance. Head mag-
netic resonance imaging (MRI) revealed no abnormal findings. A CSF examination revealed
a white blood cell count of 3/mm3 with 100% mononuclear cells, and the concentrations of
protein and glucose were within normal ranges. Multiplex-virus PCR was positive for
HHV-6 at 110,000 copies/ml but negative for HSV-1, HSV-2, VZV, CMV, BKV, and JCV. The
cause of the convulsions was considered to be HHV-6 encephalitis, and the dosage of fosca-
vir was doubled. The HHV-6 level in CSF became undetectable, and his consciousness was
normalized 2 weeks after starting the increased dose treatment. No neuropsychological
problems persisted. In this patient, it was difficult to make a diagnosis of HHV-6 encephali-
tis because he had already received preemptive therapy for HHV-6 reactivation, and ence-
phalitis due to other unknown viruses needed to be excluded first. Although multiplex-
virus PCR is useful for a prompt differential diagnosis, the risk of developing HHV-6
encephalitis should be taken into consideration when a high-blood viral load is observed,
even just once.
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3.3. Detection of viral DNA in urine samples
A total of 380 urine samples were obtained from 58 allogeneic HSCT patients who devel-
oped hematuria, micturition pain, and pollakisuria. The most frequently detected virus was
BKV in 194 of 380 samples (51.1%), followed by ADV in 65 (17.3%), JCV in 54 (14.2%), CMV
in 14 (3.7%), HHV-6 in 7 (1.8%), and EBV in 4 (1.1%) (Table 2). Herpes family viruses other
than CMV were not detected. The median copy number in BKV viruria was 1.7 × 107
copies/ml, that of ADV was 2.7 × 105copies/ml, that of JCV was 8.75 × 105 copies/ml, that of
CMV was 2.5 × 103 copies/ml, that of HHV-6 was 2.4 × 103 copies/ml, and that of EBV was 3.4
× 103 copies/ml. In 30 of 194 BKV viruria, coinfection with ADV was observed. Most EBV
and HHV-6 viruria were coinfected with BKV or JCV. The median copy number of CMV in
the plasma (6.6 × 103 copies/ml) was higher than that in the urine. CMV viruria, therefore,
might be caused by viral transposition from the blood stream to the urinary tract. By con-
trast, in 184 urine samples with detectable BKV, plasma samples were simultaneously exam-
ined for BKV, and BKV was detected in 61 plasma samples (33.2%). The median copy
number of BKV in the plasma was 5.9 × 103 copies/ml, which was lower than that in the
urine, suggesting that BKV had a greater affinity for the urinary tract. Similarly, in 47 ADV
viruria, ADV was detected in 30 plasma samples (63.8%), and the median copy number of
ADV in the plasma was 4.4 × 104 copies/ml.
Viral infections with polyomaviruses and ADV, mainly type 11, have been documented in
allogeneic HSCT patients complicated by hemorrhagic cystitis (HC) [23, 24]. Some data have
also identified CMV and HHV-6 as putative causes of HC [25, 26].
Polyomaviruses, namely BKV and JCV, are thought to cause primary infection in childhood or
early adulthood and subclinically remain in the kidney and peripheral blood in 35–85% of the
global population [27]. Although BKV has been reported to be detectable by PCR in the urine
in 5–44% of asymptomatic and immunocompetent adults [28], BK viremia has been described
in only immunocompromised patients, such as those who have undergone renal transplanta-
tion or HSCT. BKV is considered to be the main pathogen for HC in allogeneic HSCT patients
[29]. Clinical manifestations of BKV reactivation include prolonged hematuria, painful
dysuria, HC, and renal dysfunction. HC caused by polyomaviruses, however, spontaneously
resolves in most patients [30]. A few studies have reported that BK viremia may predict the
development of HC. The incidence of HC was reported to be 26–43% in allogeneic HSCT
patients, and all of them had BK viremia [31]. Erard et al. observed that adult allogeneic HSCT
patients with BKV viremia exceeding 104 copies/ml had a higher risk of developing HC than
those with viremia less than 104 copies/ml [32].
Primary ADV infection also occurs during childhood and remains latent in the genitourinary
tracts. In contrast to BKV, ADV is usually undetectable in the urine of healthy adults, indicating
that ADV does not replicate itself under normal immune conditions and that severe immu-
nosuppression allows for ADV replication [33]. The clinical manifestations of ADV are similar
to those of BKV; however, the symptoms are more severe in ADV-caused HC [34] and some-
times lead to a fatal course [35]. Echavarria et al. reported that ADV viremia was a risk factor
for the development of severe or fatal disease [36]. Thus, the early diagnosis of ADV HC using
a PCR method such as our multiplex-virus PCR assay is important, and therapeutic interven-
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tion for ADV with antiviral agents such as cidofovir should be considered if ADV is detected
in the plasma [30, 34].
4. Conclusion
Viral reactivation is a major problem and must be monitored and treated at the early stage in
immunocompromised patients to avoid a fatal outcome. The qualitative multiplex-virus PCR
assay that we recently developed is useful for screening and monitoring viral infection,
especially multiple-virus infection, which occurs under immunosuppressive conditions, such
as in patients following allogeneic HSCT. Under these conditions, the early diagnosis and
preemptive therapy for viral infection is important to prevent immunocompromised patients
from developing severe organ damage. Furthermore, quantitative real-time PCR may be useful
for evaluating the clinical relevance of virus infections. The establishment of a cutoff value to
distinguish viral reactivation from viral disease is currently difficult, as a standardized assay
system is lacking. Therefore, the standardization of the multiplex-virus PCR system, as well
as validation of its sensitivity and specificity, should be established in the future.
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